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Background
An improvement in overall survival among patients with metastatic melanoma has 
been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic 
T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response — 
administered with or without a glycoprotein 100 (gp100) peptide vaccine was com-
pared with gp100 alone in patients with previously treated metastatic melanoma.
Methods
A total of 676 HLA-A*0201–positive patients with unresectable stage III or IV mela-
noma, whose disease had progressed while they were receiving therapy for meta-
static disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus 
gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a 
dose of 3 mg per kilogram of body weight, was administered with or without gp100 
every 3 weeks for up to four treatments (induction). Eligible patients could receive 
reinduction therapy. The primary end point was overall survival.
Results
The median overall survival was 10.0 months among patients receiving ipilimumab 
plus gp100, as compared with 6.4 months among patients receiving gp100 alone 
(hazard ratio for death, 0.68; P<0.001). The median overall survival with ipilimumab 
alone was 10.1 months (hazard ratio for death in the comparison with gp100 alone, 
0.66; P = 0.003). No difference in overall survival was detected between the ipili-
mumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P = 0.76). Grade 3 
or 4 immune-related adverse events occurred in 10 to 15% of patients treated with 
ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to 
the study drugs (2.1%), and 7 were associated with immune-related adverse events.
Conclusions
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, 
improved overall survival in patients with previously treated metastatic melanoma. 
Adverse events can be severe, long-lasting, or both, but most are reversible with ap-
propriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov 
number, NCT00094653.)
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The incidence of metastatic mela­noma has increased over the past three de-cades,1,2 and the death rate continues to 
rise faster than the rate with most cancers.3 The 
World Health Organization (WHO) estimates that 
worldwide there are 66,000 deaths annually from 
skin cancer, with approximately 80% due to mel-
anoma.4 In the United States alone, an estimated 
8600 persons died from melanoma in 2009.1 The 
median survival of patients with melanoma who 
have distant metastases (American Joint Com-
mittee on Cancer stage IV) is less than 1 year.5,6 
No therapy is approved beyond the first-line ther-
apy for metastatic melanoma, and enrollment in 
a clinical trial is the standard of care. No therapy 
has been shown in a phase 3, randomized, con-
trolled trial to improve overall survival in patients 
with metastatic melanoma.6­9
Regulatory pathways that limit the immune 
response to cancer are becoming increasingly 
well characterized. Cytotoxic T-lymphocyte–asso-
ciated antigen 4 (CTLA-4) is an immune check-
point molecule that down-regulates pathways of 
T-cell activation.10 Ipilimumab, a fully human 
monoclonal antibody (IgG1) that blocks CTLA-4 
to promote antitumor immunity,11­14 has shown 
activity in patients with metastatic melanoma 
when it has been used as monotherapy in phase 2 
studies.15­17 Ipilimumab has also shown activity 
when combined with other agents,18,19 including 
cancer vaccines.20,21 One well-studied cancer vac-
cine comprises HLA-A*0201–restricted peptides 
derived from the melanosomal protein, glyco-
protein 100 (gp100). Monotherapy with this vac-
cine induces immune responses but has limited 
antitumor activity.22 However, the results of a 
recent study suggest that gp100 may improve the 
efficacy of high-dose interleukin-2 in patients 
with metastatic melanoma.23 With no accepted 
standard of care, gp100 was used as an active 
control for our phase 3 study, which evaluated 
whether ipilimumab with or without gp100 im-
proves overall survival, as compared with gp100 
alone, among patients with metastatic melano-
ma who had undergone previous treatment.
Me thods
Patients
Patients were eligible for inclusion in the study if 
they had a diagnosis of unresectable stage III or 
IV melanoma and had received a previous thera-
peutic regimen containing one or more of the 
following: dacarbazine, temozolomide, fotemus-
tine, carboplatin, or interleukin-2. Other inclu-
sion criteria were age of at least 18 years; life ex-
pectancy of at least 4 months; Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 
(fully active, able to carry on all predisease per-
formance without restriction) or 1 (restricted in 
physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary na-
ture, such as light housework or office work)24; 
positive status for HLA-A*0201; normal hemato-
logic, hepatic, and renal function; and no system-
ic treatment in the previous 28 days. Exclusion 
criteria were any other cancer from which the 
patient had been disease-free for less than 5 years 
(except treated and cured basal-cell or squamous-
cell skin cancer, superficial bladder cancer, or 
treated carcinoma in situ of the cervix, breast, or 
bladder); primary ocular melanoma; previous re-
ceipt of anti–CTLA-4 antibody or cancer vaccine; 
autoimmune disease; active, untreated metastases 
in the central nervous system; pregnancy or lac-
tation; concomitant treatment with any nonstudy 
anticancer therapy or immunosuppressive agent; 
or long-term use of systemic corticosteroids.
The protocol was approved by the institution-
al review board at each participating institution 
and was conducted in accordance with the ethi-
cal principles originating from the Declaration 
of Helsinki and with Good Clinical Practice as 
defined by the International Conference on Har-
monization. All patients (or their legal represen-
tatives) gave written informed consent before 
enrollment.
Study Design and Treatment
In this randomized, double-blind, phase 3 study, 
we enrolled patients at 125 centers in 13 coun-
tries in North America, South America, Europe, 
and Africa. Between September 2004 and August 
2008, patients were randomly assigned to one of 
three study groups, with stratification according 
to baseline metastasis stage (M0, M1a, or M1b 
vs. M1c, classified according to the tumor–node–
metastasis [TNM] categorization for melanoma 
of the American Joint Committee on Cancer), and 
receipt or nonreceipt of previous interleukin-2 
therapy. The full original protocol, a list of amend-
ments, and the final protocol, as well as the sta-
tistical analysis plan, are available with the full 
text of this article at NEJM.org.
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Patients were randomly assigned, in a 3:1:1 
ratio, to treatment with an induction course of 
ipilimumab, at a dose of 3 mg per kilogram of 
body weight, plus a gp100 peptide vaccine; ipi-
limumab plus gp100 placebo; or gp100 plus ipi-
limumab placebo — all administered once every 
3 weeks for four treatments. In the vaccine 
groups, patients received two modified HLA-
A*0201–restricted peptides, injected subcutane-
ously as an emulsion with incomplete Freund’s 
adjuvant (Montanide ISA-51): a gp100:209-
217(210M) peptide, 1 mg injected in the right 
anterior thigh, and a gp100:280-288(288V) pep-
tide, 1 mg injected in the left anterior thigh. 
Peptide injections were given immediately after 
a 90-minute intravenous infusion of ipilimumab 
or placebo. Treatment began on day 1 of week 1, 
and if there were no toxic effects that could not 
be tolerated, no rapidly progressive disease, and 
no significant decline in performance status, 
patients received an additional treatment during 
weeks 4, 7, and 10. Patients in whom new lesions 
developed or baseline lesions grew were allowed 
to receive additional treatments to complete induc-
tion. Patients with stable disease for 3 months’ 
duration after week 12 or a confirmed partial or 
complete response were offered additional courses 
of therapy (reinduction) with their assigned treat-
ment regimen if they had disease progression.
The original primary end point was the best 
overall response rate (i.e., the proportion of pa-
tients with a partial or complete response). The 
primary end point was amended to overall sur-
vival (with the amendment formally approved on 
January 15, 2009) in the ongoing blinded study, 
on the basis of phase 2 data and in alignment 
with another ongoing phase 3 trial of ipilimu-
mab involving patients with metastatic melano-
ma.25 The primary comparison in overall sur-
vival was between the ipilimumab-plus-gp100 
group and the gp100-alone group. Prespecified 
secondary end points included a comparison of 
overall survival between the ipilimumab-alone 
and the gp100-alone groups and between the 
two ipilimumab groups, the best overall response 
rate, the duration of response, and progression-
free survival. Subgroup comparisons of overall 
survival were performed across five prespecified 
categories: metastasis stage (M0, M1a, or M1b 
vs. M1c), receipt or nonreceipt of previous inter-
leukin-2 therapy, baseline levels of serum lactate 
dehydrogenase (less than or equal to the upper 
limit of the normal range vs. higher than the 
upper limit of the normal range), age (<65 years 
vs. ≥65 years), and sex.
The trial was designed jointly by the senior 
academic authors and the sponsors, Medarex 
and Bristol-Myers Squibb. Data were collected by 
the sponsors and analyzed in collaboration with 
the senior academic authors, who vouch for the 
completeness and accuracy of the data and 
analyses and for the conformance of this report 
to the protocol, as amended. An initial draft of 
the manuscript was prepared by six of the aca-
demic authors in collaboration with the sponsor 
and a professional medical writer paid by the 
sponsor. All the authors contributed to subse-
quent drafts and made the decision to submit 
the manuscript for publication. All the authors 
signed a confidentiality disclosure agreement 
with the sponsor.
Assessments
For the assessment of a patient’s eligibility, each 
patient’s HLA-A*0201 status was determined at a 
central laboratory. Patients who met the study 
criteria were assigned to receive treatment within 
35 days after HLA typing and within 28 days af-
ter diagnostic imaging. Computed tomography 
with contrast material or magnetic resonance 
imaging of the brain, chest, abdomen, pelvis, 
and other anatomical regions, as clinically indi-
cated, was performed. Cutaneous lesions were 
photographed. Tumor assessments were per-
formed at baseline, and all patients who did not 
have documented early disease progression and 
who had stable disease or better at week 12 had 
confirmatory scans at weeks 16 and 24 and every 
3 months thereafter. Tumor responses were de-
termined by the investigators with the use of 
modified WHO criteria to evaluate bidimension-
ally measurable lesions.26
Adverse events were graded according to the 
National Cancer Institute’s Common Terminol-
ogy Criteria for Adverse Events, version 3.0. An 
immune-related adverse event was defined as an 
adverse event that was associated with exposure 
to the study drug and that was consistent with 
an immune phenomenon. Protocol guidelines 
for the management of immune-related adverse 
events included the administration of cortico-
steroids (orally or intravenously), a delay in a 
scheduled dose, or discontinuation of thera-
py.15­17 Assigned doses were delayed in the case 
of nondermatologic immune-related adverse 
events of grade 2 or higher until the event im-
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proved to grade 1 or lower; if the event did not 
improve to grade 1 or lower, treatment was dis-
continued permanently. Monitoring of adverse 
events continued for at least 70 days after the 
last dose of study drugs had been administered 
or until any ongoing event resolved or stabilized. 
All patients, including those with low-grade 
changes in bowel frequency or stool consistency, 
were followed closely. A data and safety moni-
toring committee provided independent over-
sight of safety and the risk–benefit ratio.
During the study enrollment, the following 
stopping rule was in place: if 10% or more of the 
patients in any study treatment group, evaluated 
cumulatively every 3 months, had a nondermato-
logic-related toxic adverse event of grade 3 or 
higher that was attributable to the investigational 
agents and that could not be alleviated or con-
trolled by appropriate care or corticosteroid ther-
apy within 14 days after the initiation of sup-
portive care or corticosteroid therapy, assignment 
of patients to that study group would be sus-
pended until the sponsor and the data and safety 
monitoring committee had reviewed the events 
and determined the appropriate course of action.
Statistical Analysis
The original study sample size of 750 patients 
was determined on the basis of the primary end 
point of best overall response rate but was re-
vised with the new primary end point of overall 
survival. We estimated that with 385 events 
(deaths) among a total of 500 patients randomly 
assigned to the ipilimumab-plus-gp100 and the 
gp100-alone groups, the study would have at 
least 90% power to detect a difference in overall 
survival, at a two-sided alpha level of 0.05, with 
the use of a log-rank test. A total of 481 events 
were required in all three groups (assuming that 
the events were distributed in a 3:1:1 ratio in the 
ipilimumab-plus-gp100, ipilimumab-alone, and 
gp100-alone groups, respectively). Therefore, all 
patients who were randomly assigned in the 
study were to be followed until at least 481 events 
had occurred in the study. Enrollment was com-
pleted on July 25, 2008, when more than 650 pa-
tients had been enrolled. A post hoc power anal-
ysis showed that the 219 events observed among 
a total of 273 patients randomly assigned to the 
ipilimumab-alone and gp100-alone groups pro-
vided at least 80% power to detect a difference in 
overall survival between the two groups, at a 
two-sided alpha level of 0.05, with the assump-
tion that ipilimumab alone has the same treat-
ment effect as the combination regimen of ipili-
mumab plus gp100.
Survival was defined as the time from ran-
domization to death from any cause, and pro-
gression-free survival as the time from random-
ization to documented disease progression or 
death. Event-time distributions were estimated 
with the use of the Kaplan–Meier method. Cox 
proportional-hazards models, stratified accord-
ing to metastasis status and receipt or nonre-
ceipt of previous interleukin therapy, were used 
to estimate hazard ratios and to test for sig-
nificance of the timing of events. All reported 
P values are two-sided, and confidence intervals 
are at the 95% level. Survival rates were based on 
Kaplan–Meier estimation, and confidence inter-
vals were calculated with the use of the boot-




Among 676 patients enrolled in the study, 403 
were randomly assigned to receive ipilimumab 
plus gp100, 137 to receive ipilimumab alone, and 
136 to receive gp100 alone (control group) (Fig. 1 
in the Supplementary Appendix, available at 
NEJM.org). Included among these patients were 
82 patients who had metastases in the central 
nervous system at baseline, of whom 77 received 
the study drug. The baseline characteristics of 
the patients are shown in Table 1. Efficacy analy-
ses were performed on the intention-to-treat 
population, which included all patients who had 
undergone randomization (676 patients). The 
safety population included all patients who had 
undergone randomization and who had received 
any amount of study drug (643 patients). A total 
of 242 of 403 patients in the ipilimumab-plus-
gp100 group (60.0%), 88 of 137 in the ipilimu-
mab-alone group (64.2%), and 78 of 136 in the 
gp100-alone group (57.4%) received all four ipi-
limumab doses or placebo infusions. The most 
frequent reason for discontinuation of therapy 
was disease progression.
Efficacy
All the analyses of the efficacy end points re-
ported here were prespecified as per protocol. 
The New England Journal of Medicine 
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Patients were followed for up to 55 months, with 
median follow-up times for survival of 21.0 
months in the ipilimumab-plus-gp100 group, 
27.8 months in the ipilimumab-alone group, and 
17.2 months in the gp100-alone group. The me-
dian overall survival in the ipilimumab-plus-
gp100 group was 10.0 months (95% confidence 
interval [CI], 8.5 to 11.5), as compared with 6.4 
months (95% CI, 5.5 to 8.7) in the gp100-alone 
group (hazard ratio for death, 0.68; P<0.001). 
The median overall survival in the ipilimumab-
alone group was 10.1 months (95% CI, 8.0 to 
13.8) (hazard ratio for death with ipilimumab 
alone as compared with gp100 alone, 0.66; 
P = 0.003). No difference in overall survival was 
detected between the two ipilimumab groups 
(hazard ratio for death with ipilimumab plus 
gp100, 1.04; P = 0.76) (Fig. 1). Analyses of sur-
vival showed that the rates of overall survival in 
the ipilimumab-plus-gp100 group, the ipilimu -
mab-alone group, and the gp100-alone group, 
respectively, were 43.6%, 45.6%, and 25.3% at 12 
months, 30.0%, 33.2%, and 16.3% at 18 months, 
and 21.6%, 23.5%, and 13.7% at 24 months. The 
Table 1. Baseline Characteristics of the Patients.*
Variable
Ipilimumab  









Mean age — yr 55.6 56.8 57.4 56.2
Sex — no. (%)
Male 247 (61.3) 81 (59.1) 73 (53.7) 401 (59.3)
Female 156 (38.7) 56 (40.9) 63 (46.3) 275 (40.7)
ECOG performance status — no. (%)†
0 232 (57.6) 72 (52.6) 70 (51.5) 374 (55.3)
1 166 (41.2) 64 (46.7) 61 (44.9) 291 (43.0)
2  4 (1.0) 1 (0.7) 4 (2.9)  9 (1.3)
3  1 (0.2) 0 0  1 (0.1)
Unknown 0 0 1 (0.7)  1 (0.1)
M stage — no. (%)‡
M0  5 (1.2) 1 (0.7) 4 (2.9) 10 (1.5)
M1a 37 (9.2) 14 (10.2) 11 (8.1) 62 (9.2)
M1b  76 (18.9) 22 (16.1) 23 (16.9) 121 (17.9)
M1c 285 (70.7) 100 (73.0) 98 (72.1) 483 (71.4)
Lactate dehydrogenase level — no. (%)
≤Upper limit of the normal range 252 (62.5) 84 (61.3) 81 (59.6) 417 (61.7)
>Upper limit of the normal range 149 (37.0) 53 (38.7) 52 (38.2) 254 (37.6)
Unknown  2 (0.5) 0 3 (2.2)  5 (0.7)
CNS metastases at baseline — no. (%)  46 (11.4) 15 (10.9) 21 (15.4)  82 (12.1)
Received study drug  42 (10.4) 15 (10.9) 20 (14.7)  77 (11.4)
Had had previous treatment for CNS 
 metastases
39 (9.7) 15 (10.9) 19 (14.0)  73 (10.8)
Previous systemic therapy for metastatic 
 disease — no. (%)
 403 (100.0) 137 (100.0) 136 (100.0)  676 (100.0)
Previous interleukin-2 therapy — no. (%)  89 (22.1) 32 (23.4) 33 (24.3) 154 (22.8)
* Percentages may not total 100 because of rounding. CNS denotes central nervous system.
† The Eastern Cooperative Oncology Group (ECOG) status ranges from 0 to 5, with higher scores indicating greater im-
pairment (5 indicates death).
‡ The metastasis (M) stage was classified according to the tumor–node–metastasis (TNM) categorization for melanoma 
of the American Joint Committee on Cancer.
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effect of ipilimumab on overall survival was inde-
pendent of age, sex, baseline serum lactate dehy-
drogenase levels, metastasis stage of disease, 
and receipt or nonreceipt of previous interleu-
kin-2 therapy (Fig. 2).
A 19% reduction in the risk of progression 
was noted with ipilimumab plus gp100, as com-
pared with gp100 alone (hazard ratio, 0.81; 
P<0.05), and a 36% reduction in risk of progres-
sion was seen with ipilimumab alone as com-
pared with gp100 alone (hazard ratio, 0.64; 
P<0.001). The reduction in risk with ipilimumab 
plus gp100 was less than that with ipilimumab 
alone (hazard ratio with ipilimumab plus gp100, 
1.25; P = 0.04). The median values for progres-
sion-free survival were similar in all groups at 
the time of the first assessment of progression 
(week 12), after which there was a separation 
between the curves (Fig. 1B).
The highest percentage of patients with an 
objective response or stable disease was in the 
ipilimumab-alone group (Table 2); this group 
had a best overall response rate of 10.9% and a 
disease control rate (the proportion of patients 
with a partial or complete response or stable 
disease) of 28.5%. In the ipilimumab-alone group, 
9 of 15 patients (60.0%) maintained an objective 
response for at least 2 years (26.5 to 44.2 months 
[ongoing]), and in the ipilimumab-plus-gp100 
group, 4 of 23 patients (17.4%) maintained the 
response for at least 2 years (27.9 to 44.4 months 
[ongoing]). Neither of the two patients in the 
gp100-alone group who had a partial response 
maintained the response for 2 years. Responses 
to ipilimumab continued to improve beyond week 
24: in the ipilimumab-plus-gp100 group, 3 pa-
tients with disease progression improved to stable 
disease, 3 with stable disease improved to a par-
tial response, and 1 with a partial response im-
proved to a complete response; in the ipilimu-
mab-alone group, 2 patients with stable disease 
improved to a partial response and 3 with a 
partial response improved to a complete re-
sponse. Among 31 patients given reinduction 
therapy with ipilimumab, a partial or complete 
response or stable disease was achieved by 21 
(Table 2).
Adverse Events
The adverse events reported in the safety popu-
lation are listed in Table 3. The most common 
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Figure 1. Kaplan–Meier Curves for Overall Survival and Progression-free 
Survival in the Intention-to-Treat Population.
The median follow-up for overall survival (Panel A) in the ipilimumab (Ipi)-
plus-glycoprotein 100 (gp100) group was 21.0 months, and the median 
overall survival was 10.0 months (95% CI, 8.5 to 11.5); in the ipilimumab-
alone group, the median follow-up was 27.8 months, and the median over-
all survival, 10.1 months (95% CI, 8.0 to 13.8); and in the gp100-alone 
group, the median follow-up was 17.2 months, and the median overall sur-
vival, 6.4 months (95% CI, 5.5 to 8.7). The median progression-free survival 
(Panel B) was 2.76 months (95% CI, 2.73 to 2.79) in the ipilimumab-plus-
gp100 group, 2.86 months (95% CI, 2.76 to 3.02) in the ipilimumab-alone 
group, and 2.76 months (95% CI, 2.73 to 2.83) in the gp100-alone group. 
The rates of progression-free survival at week 12 were 49.1% (95% CI, 44.1 
to 53.9) in the ipilimumab-plus-gp100 group, 57.7% (95% CI, 48.9 to 65.5) 
in the ipilimumab-alone group, and 48.5% (95% CI, 39.6 to 56.7) in the 
gp100-alone group.
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Figure 2. Subgroup Analyses of Overall Survival.
The prespecified analyses of overall survival among subgroups of patients, as defined by baseline demographic 
characteristics and stratification factors (metastasis [M] stage, classified according to the tumor–node–metastasis 
[TNM] categorization for melanoma of the American Joint Committee on Cancer; and receipt or nonreceipt of inter-
leukin-2 therapy), showed that hazard ratios were lower than 1 (indicating a lower risk of death) for each subgroup 
in the ipilimumab (Ipi)-plus-glycoprotein 100 (gp100) group as compared with the gp100-alone group (Panel A) and 
for each subgroup in the ipilimumab-alone group as compared with the gp100-alone group (Panel B). Hazard ratios 
were estimated with the use of unstratified Cox proportional-hazards models. Horizontal lines represent 95% confi-
dence intervals. LDH denotes lactate dehydrogenase, and ULN the upper limit of the normal range.
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Table 2. Best Response to Treatment and Time-to-Event Data.*
Response and Time to Event
Ipilimumab  





gp100 Alone  
(N = 136)
Overall survival
Total no. of deaths 306 100 119
Comparison with gp100 alone
Hazard ratio (95% CI) 0.68 (0.55–0.85) 0.66 (0.51–0.87) —
P value by log-rank test <0.001 0.003 —
Comparison with ipilimumab alone
Hazard ratio (95% CI) 1.04 (0.83–1.30) — —
P value by log-rank test 0.76 — —
Evaluation of therapy
Induction
Best overall response — no. (%)
Complete response  1 (0.2)  2 (1.5) 0
Partial response 22 (5.5) 13 (9.5)  2 (1.5)
Stable disease  58 (14.4)  24 (17.5) 13 (9.6)
Progressive disease 239 (59.3)  70 (51.1)  89 (65.4)
Not evaluated  83 (20.6)  28 (20.4)  32 (23.5)
Best overall response rate — % (95% CI) 5.7 (3.7–8.4) 10.9 (6.3–17.4) 1.5 (0.2–5.2)
P value for comparison with gp100 alone 0.04 0.001 —
P value for comparison with ipilimumab alone 0.04 — —
Disease control rate — % (95% CI)† 20.1 (16.3–24.3) 28.5 (21.1–36.8) 11.0 (6.3–17.5)
P value for comparison with gp100 alone 0.02 <0.001 —
P value for comparison with ipilimumab alone 0.04 — —
Time to event — mo
Time to progression — median (95% CI) 2.76 (2.73–2.79) 2.86 (2.76–3.02) 2.76 (2.73–2.83)
Time to response — mean (95% CI) 3.32 (2.91–3.74) 3.18 (2.75–3.60) 2.74 (2.12–3.37)
Duration of response — median (95% CI) 11.5 (5.4–NR) NR (28.1–NR) NR (2.0–NR)
Reinduction‡
Best overall response — no./total no. (%)
Complete response 0 1/8 (12.5) 0
Partial response  3/23 (13.0) 2/8 (25.0) 0
Stable disease 12/23 (52.2) 3/8 (37.5) 0
Progressive disease  8/23 (34.8) 2/8 (25.0) 1/1 (100.0)
* Of the 143 patients who could not be evaluated for a response, 33 patients did not receive any study drug and 110 pa-
tients did not have baseline or week-12 tumor assessments (or both). Percentages may not total 100 because of round-
ing. NR denotes not reached.
† The disease control rate is the percentage of patients with a partial or complete response or stable disease.
‡ A total of 40 patients (29 in the ipilimumab-plus-gp100 group; 9 in the ipilimumab-alone group, and 2 in the gp100-
alone group) were given reinduction therapy, but 8 were not included in the efficacy analyses: 3 had major protocol vio-
lations and 5 were not eligible owing to the fact that they had had a best overall response of progressive disease during 
induction and were given reinduction therapy inadvertently.
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immune-related events, which occurred in approx-
imately 60% of the patients treated with ipilimu-
mab and 32% of the patients treated with gp100. 
The frequency of grade 3 or 4 immune-related 
adverse events was 10 to 15% in the ipilimumab 
groups and 3.0% in the gp100-alone group. All 
immune-related events occurred during the in-
duction and reinduction periods; the immune-
related adverse events most often affected the 
skin and gastrointestinal tract. The median time 
to the resolution of immune-related adverse 
events of grade 2, 3, or 4 was 6.3 weeks (95% CI, 
4.3 to 8.4) in the ipilimumab-plus-gp100 group, 
4.9 weeks (95% CI, 3.1 to 6.4) in the ipilimumab-
alone group, and 3.1 weeks (95% CI, 1.1 to not 
reached) in the gp100-alone group.
The most common immune-related adverse 
event was diarrhea, which occurred at any grade 
in 27 to 31% of the patients in the ipilimumab 
groups. After the administration of corticoste-
roids, the median time to the resolution of diar-
rhea of grade 2 or higher was 2.0 weeks for 40 
of 44 patients in the ipilimumab-plus-gp100 
group and 2.3 weeks for 14 of 15 patients in the 
ipilimumab-alone group. In addition to cortico-
steroids, 4 patients received infliximab (anti–
tumor necrosis factor α antibody) for diarrhea of 
grade 3 or higher or colitis. Among the 94 per-
sons who survived for 2 years, residual effects of 
adverse events included those related to injection-
site reactions (16 patients), vitiligo (12), diarrhea 
or colitis (e.g., proctocolitis with rectal pain) (4), 
and endocrine immune-related adverse events (e.g., 
inflammation of the pituitary) that required 
hormone-replacement therapy (8). Ongoing events 
in the persons who survived for 2 years included 
rash, pruritus, diarrhea, anorexia, and fatigue, 
generally of grade 1 or 2 (in 5 to 15% of the 
patients) and grade 3 leukocytosis (in one pa-
tient). There were 14 deaths related to the study 
drugs (2.1%), of which 7 were associated with 
immune-related adverse events.
Discussion
This phase 3 study showed that ipilimumab, ei-
ther alone or with gp100, improved overall sur-
vival as compared with gp100 alone in patients 
with metastatic melanoma who had undergone 
previous treatment. More than 70% of the pa-
tients had M1c disease (presence of visceral me-
tastases) and more than 36% had elevated lactate 
dehydrogenase levels, both of which are associ-
ated with very poor survival.27,28 The eligibility 
criteria for patients in this study included HLA-
A*0201–positive status, on the basis of the mech-
anism of action of gp100. However, CTLA-4 
blockade by ipilimumab is independent of HLA 
status, as indicated by efficacy and safety out-
comes in earlier clinical trials that were similar 
between HLA-A*0201–positive and HLA-A*0201–
negative patients21 (and unpublished data).
In our study, the efficacy of ipilimumab was 
not improved by the addition of gp100. It is un-
likely that this is due to a lack of gp100 expres-
sion in the tumors, because differentiation anti-
gens have been shown to be strongly expressed 
in more than 90% of melanoma tumors, regard-
less of stage.29 Some studies of adjuvant therapy 
for melanoma showed that patients who were ad-
ministered non–gp100 vaccines had shorter sur-
vival than did patients in the control groups.30,31 
In contrast, phase 3 trials showed that in sub-
groups of patients with melanoma, vaccines had 
clinical activity when used as either adjuvant 
therapy or therapy for metastatic disease.32,33 
Cumulative data show that gp100-based vaccines 
have immunologic activity, although clinical ac-
tivity is minimal when gp100 vaccines are ad-
ministered as monotherapy.22 In a randomized, 
phase 3 study involving patients with metastatic 
melanoma, a significant improvement in pro-
gression-free survival and response rate, and a 
nonsignificant improvement in overall survival, 
were seen with gp100-plus-high-dose interleu-
kin-2, as compared with interleukin-2 alone.23 
Although gp100 appeared to attenuate ipilimu-
mab responses in our study, it is important to 
consider the fact that some radiographic re-
sponses of immunotherapeutic agents are not 
captured by standard response criteria.34 Regard-
less, such effects of gp100 did not translate into 
a difference in overall survival between the two 
ipilimumab groups.
The data in this study are consistent with the 
results of phase 2 trials of ipilimumab mono-
therapy in the same patient population.15­17 The 
data from phase 2 studies suggest that there is 
a long-term survival effect of ipilimumab mono-
therapy; ipilimumab monotherapy at a dose of 
3 mg per kilogram resulted in 1-year and 2-year 
survival rates of 39.3% and 24.2%, respectively.16 
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The long-term effect of ipilimumab in our study 
is shown by survival analyses at late time points, 
which showed 1-year and 2-year survival rates of 
45.6% and 23.5%, respectively. In recent, ran-
domized, phase 3 trials involving patients with 
unresectable stage III or IV melanoma who had 
received previous treatment, 1-year survival rates 
were reported to be 22% to 38% with various 
treatment regimens.35,36 The median overall sur-
vival in these studies ranged from 5.9 to 9.7 
months. Neither these nor other randomized, 
controlled trials had shown a significant im-
provement in overall survival.
The adverse-event profile of ipilimumab in 
this study is consistent with that reported in 
phase 2 trials,15­17 with the majority of adverse 
events being immune-related and consistent 
with the proposed mechanism of action of ipi-
limumab.11­14 As shown in phase 2 studies, 
prompt medical attention and early administra-
tion of corticosteroids are critical to the man-
agement of immune-related adverse events.15­17 
Management guidelines (algorithms) for immune-
related adverse events involve close patient follow-
up and the administration of high-dose systemic 
corticosteroids — which were used as necessary 
in our study — for grade 3 or 4 events.37,38
In conclusion, this randomized, controlled 
trial showed that there was a significant improve-
ment in overall survival among patients with 
metastatic melanoma. In some patients, side ef-
fects can be life-threatening and may be treat-
ment-limiting. Reinduction with ipilimumab at 
the time of disease progression can result in fur-
ther clinical benefit. Overall, our findings suggest 
that the T-cell potentiator ipilimumab may be use-
ful as a treatment for patients with metastatic 
melanoma whose disease progressed while they 
were receiving one or more previous therapies.
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